Gossamer Bio (GOSS) EBITDA Margin (2022 - 2025)
Historic EBITDA Margin for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to 362.87%.
- Gossamer Bio's EBITDA Margin fell 198700.0% to 362.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 793.2%, marking a year-over-year decrease of 7236400.0%. This contributed to the annual value of 60.63% for FY2024, which is N/A changed from last year.
- Latest data reveals that Gossamer Bio reported EBITDA Margin of 362.87% as of Q3 2025, which was down 198700.0% from 370.24% recorded in Q2 2025.
- In the past 5 years, Gossamer Bio's EBITDA Margin ranged from a high of 1710.33% in Q3 2022 and a low of 390.85% during Q1 2025
- In the last 4 years, Gossamer Bio's EBITDA Margin had a median value of 202.5% in 2024 and averaged 619.62%.
- Examining YoY changes over the last 5 years, Gossamer Bio's EBITDA Margin showed a top increase of -198700bps in 2025 and a maximum decrease of -4217200bps in 2025.
- Gossamer Bio's EBITDA Margin (Quarter) stood at 1612.76% in 2022, then decreased by -13bps to 1400.77% in 2023, then plummeted by -86bps to 202.5% in 2024, then tumbled by -279bps to 362.87% in 2025.
- Its EBITDA Margin stands at 362.87% for Q3 2025, versus 370.24% for Q2 2025 and 390.85% for Q1 2025.